Halo: Treating DMD symptoms

Most companies developing therapeutics for Duchenne muscular dystrophy are targeting the genetic defects that cause the disease. Halo Therapeutics LLC, a company funded by two patient groups, thinks there is still room for treatments to improve the manifestations of DMD. Its HT-100 is designed to address the fibrosis and lack of muscle regeneration that characterize the disease.

DMD is an X chromosome-linked disease that arises from a mutation in the dystrophin gene, resulting in a lack of the dystrophin protein, which acts as a scaffold and shock absorber in muscle fibers...